Delta tocotrienol has anti-neoplastic activity as demonstrated in several in-vitro and in-vivo investigations. The effect relies on inhibition of different pathways. It also antiangiogenic activity, an additive to bevacizumab may be expected. present study was a phase II trial combined with chemotherapy refractory ovarian cancer. included analysis circulating tumor specific HOXA9 methylated DNA (HOXA9 meth-ctDNA) during treatment. 23 patients. rate disease stabilization 70% very low...

The early identification of treatment effect is wanted in several settings, including the management metastatic colorectal cancer (mCRC). A potential universal marker circulating tumor DNA (ctDNA). Our prospective study explored association between progression-free survival (PFS) and overall (OS), change ctDNA after one cycle chemotherapy patients with mCRC.The included mCRC receiving standard first line combination 5-Fluorouracil (FU), oxaliplatin, bevacizumab. Hypermethylated neuropeptide...

AimThe aim of the study was to compare ctDNA response rate and objective as surrogate markers for overall survival (OS) in patients with metastatic cancer treated chemotherapy.MethodsThe included 420 distributed five cohorts colorectal, ovarian, non–small cell lung cancer. It represents a retrospective analysis enrolled prospective biomarker studies clinical trials. All had measured before start treatment at first evaluation response. defined fraction converting from measurable level...

This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve clinical validity ctDNA monitoring in metastatic setting solid tumors.

Precision medicine calls for an early indicator of treatment efficiency. Circulating tumor DNA (ctDNA) is a promising marker in this setting. Our prospective study explored the association between disease development and change ctDNA during first line chemotherapy patients with RAS/RAF mutated metastatic colorectal cancer (mCRC). The included 138 mCRC receiving standard treatment. In same mutation was quantified plasma using droplet digital PCR. fractional abundance assessed before start at...

There is a need for biomarkers to improve the clinical benefit from systemic treatment of colorectal cancer. We designed prospective, study where patients receiving regorafenib as last-line had sequential blood samples drawn. Effect and toxicity was monitored. The primary endpoint progression free survival (PFS). Cell-free circulating tumor (ct) DNA measured either fraction with Neuropeptide Y (NPY) methylated or KRAS/NRAS/BRAF mutated ctDNA. One hundred were included three Danish centers....

INTRODUCTION: The aim of the present study was to analyze possible correlation between Natural Killer (NK) cell activity as measured by NK Vue assay and treatment efficacy in patients with disseminated cancer. MATERIALS AND METHODS: included four trials encompassing palliative treatment, i.e. one trial on prostate- ovarian cancer, respectively, two colorectal current results are based 93 mature data effect. Blood samples were collected at baseline prior each cycle into Vue. Following 24...

Despite several limitations, the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) are still gold standard response evaluation of metastatic colorectal cancer (mCRC). The aim present study was to investigate hypermethylated neuropeptide Y circulating tumor DNA (meth-NPY) as an early biomarker for treatment effect and monitoring 70 mCRC patients receiving first-line FOLFOXIRI-Toco trial. Meth-NPY analyzed using droplet digital PCR, rate defined fraction converting from a...

Abstract The impact of RAS / RAF mutations in localized colon cancer needs clarification. Based on analysis tumor‐specific DNA , this study aimed at elucidating the prognostic influence mutational status tumor and serum using an extended panel mutations. retrospectively included 294 patients with curatively resected stage I–III adenocarcinoma colon. Mutations were determined time surgery. Analyses performed droplet digital PCR technology. Hazard ratio ( HR ) for association between survival...

Triplet chemotherapy might be more effective than doublet in metastatic colorectal cancer (mCRC), but it may also marked by increased toxicity. To investigate whether δ-tocotrienol, a vitamin E analogue, with possible neuroprotective and anti-inflammatory effects, reduces the toxicity of triplet chemotherapy, we conducted randomized, double-blind, placebo-controlled trial mCRC patients receiving first-line 5-fluorouracil, oxaliplatin irinotecan (FOLFOXIRI).Seventy were randomly assigned...

PURPOSE Analysis of circulating tumor DNA (ctDNA) is a potential improvement in precision medicine. In colorectal cancer (CRC), somatic mutations such as RAS and RAF the blood (mut-ctDNA) are investigated for prognostic predictive purposes. However, they only present approximately 60% patients. Recently, ctDNA has been detected patients with RAS/ wild type (WT) by methylated (meth-ctDNA). The aim this study was to compare mutated malignant nonmalignant tissue plasma from CRC cohorts...

The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS progression-free (PFS) metastatic CRC (mCRC). It also first to explore initial change level OS, PFS CT response evaluation. included 132 patients with mCRC treated chemotherapy (FOLFIRI) or without an EGFR-inhibitor. Blood samples were drawn before treatment cycle second cycle. levels determined...

12029 Background: Prediction of treatment effect remains an unsolved problem in patients with malignant tumors. The aim the present study was to analyze possible correlation between Natural Killer (NK) cell activity as measured by NK Vue assay and different Methods: included four trials encompassing palliative prostate, ovarian colorectal cancer. current results are based on 93 mature data effect. Blood samples were collected at baseline prior each cycle into Promoca tubes placed incubator...

Diagnosing lung cancer requires invasive procedures with high risk of complications. Methylated tumor DNA in bronchial lavage has previously shown potential as a diagnostic biomarker. We aimed to develop and validate methylated HOXA9 biomarker cancer. Participants were referred on suspicion Ten mL fluid was collected at bronchoscopy for analysis based droplet digital PCR according our published method. status compared the final diagnosis. The Discovery Validation cohorts consisted 101 95...

2052 Background: Concomitant temozolomide (T) and radiotherapy (RT) is standard care in patients (pts) with newly diagnosed glioblastoma (GBM). Bevacizumab (B) irinotecan (I) produces impressive responses as second-line therapy. However, it unclear how efficacy from BI compares to BT. This study explored if should be further investigated first-line phase III setting. Methods: Pts previously untreated GBM after primary surgery/biopsy were randomized neoadjuvant (neo) chemotherapy (chemo)...

Aim: Clinical utility of the dynamics ctDNA is sparse. This study aimed at evaluating prognostic impact early in patients with metastatic cancer treated chemotherapy. Materials & methods: The were evaluated 595 using droplet digital PCR. Results: Patients an increase after one treatment cycle (n = 73; 12.2%) had overall survival 5.6 months compared 8.6 stable or decreasing 328; 55.1%) and 21.0 undetectable (p < 0.001; hazard ratio: 0.47; 95% CI: 0.41-0.53). Conclusion: Early hold important...

3593 Background: Personalized medicine calls for an early indicator of treatment failure. Circulating tumor DNA (ctDNA) is a promising marker in this setting and our prospective study explored the association between disease control change ctDNA during first line chemotherapy patients with RAS/RAF mutated metastatic colorectal cancer (mCRC). Methods: The present included 138 mCRC receiving standard combination chemotherapy. In same mutation was quantified plasma using droplet digital PCR...

2625 Background: Epithelial ovarian cancer (EOC) is a highly malignant disease with fatal outcome for most patients. During recent years immunological mechanisms have proven important in relation to the treatment and prognosis of cancer, but within EOC knowledge still sparse. Understanding importance immune markers essential future EOC. The aim present study was investigate prognostic impact intratumoral PDL-1 expression, T cells, neutrophil granulocytes (NG) Natural Killer (NK) cells...

3047 Background: A considerable fraction of lung cancer patients raise diagnostic challenges requiring invasive procedures with a certain risk complications. Therefore, new tools are major interest. Aberrant methylation the HOXA9 gene occurs in almost all malignant tumors and methylated DNA (meth-ctDNA) is shed into circulation. The present study aimed at prospective investigation possible value meth-ctDNA bronchial lavage (BL). Methods: Patients enrolled were referred from general...